Logo-bi
BioImpacts. 2021;11(1): 65-84. doi: 10.34172/bi.2021.11
PMID: 33469510        PMCID: PMC7803919

Original Research

A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines

Mohammad Mostafa Pourseif 1 ORCID, Sepideh Parvizpour 1, Behzad Jafari 2,1, Jaber Dehghani 1 ORCID, Behrouz Naghili 3, Yadollah Omidi 4 * ORCID

Cited by CrossRef: 29

1- Althurwi H, Alharthy K, Albaqami F, Altharawi A, Javed M, Muhseen Z, Tahir ul Qamar M. mRNA-Based Vaccine Designing against Epstein-Barr Virus to Induce an Immune Response Using Immunoinformatic and Molecular Modelling Approaches. IJERPH. 2022;19(20):13054 [Crossref]
2- Albaqami F, Altharawi A, Althurwi H, Alharthy K, Qasim M, Muhseen Z, Tahir ul Qamar M, Hassan S. Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever. BioMed Research International. 2023;2023:1 [Crossref]
3- Masoudi-Sobhanzadeh Y, Salemi A, Pourseif M, Jafari B, Omidi Y, Masoudi-Nejad A. Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries. 2021;22(6) [Crossref]
4- Aljindan R, Al-Subaie A, Al-Ohali A, Kumar D T, Doss C G, Kamaraj B. Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach. Computers in Biology and Medicine. 2021;135:104654 [Crossref]
5- Tahir ul Qamar M, Ahmad S, Fatima I, Ahmad F, Shahid F, Naz A, Abbasi S, Khan A, Mirza M, Ashfaq U, Chen L. Designing multi-epitope vaccine against Staphylococcus aureus by employing subtractive proteomics, reverse vaccinology and immuno-informatics approaches. Computers in Biology and Medicine. 2021;132:104389 [Crossref]
6- Dehghani J, Movafeghi A, Mathieu-Rivet E, Mati-Baouche N, Calbo S, Lerouge P, Bardor M. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. Marine Drugs. 2022;20(11):657 [Crossref]
7- Wadapurkar R, Singh S, Singh A. Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine. Vaccine. 2024;42(7):1630 [Crossref]
8- Speth R. An opinion on the impacts of COVID-19 worldwide. Bioimpacts. 2022;12(3):293 [Crossref]
9- Pourseif M, Masoudi-Sobhanzadeh Y, Azari E, Parvizpour S, Barar J, Ansari R, Omidi Y. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization. Drug Discovery Today. 2022;27(11):103341 [Crossref]
10- Ahmadi M. Would the interference phenomenon be applied as an alternative option for prophylaxis against COVID-19?. Bioimpacts. 2020;11(3):169 [Crossref]
11- Moradi M, Golmohammadi R, Najafi A, Moosazadeh Moghaddam M, Fasihi-Ramandi M, Mirnejad R. A contemporary review on the important role of in silico approaches for managing different aspects of COVID-19 crisis. Informatics in Medicine Unlocked. 2022;28:100862 [Crossref]
12- Silva-Pilipich N, Beloki U, Salaberry L, Smerdou C. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines. 2024;12(3):318 [Crossref]
13- Maison D, Ching L, Cleveland S, Tseng A, Nakano E, Shikuma C, Nerurkar V. Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines. Commun Biol. 2022;5(1) [Crossref]
14- Warwicker J. A model for pH coupling of the SARS-CoV-2 spike protein open/closed equilibrium. 2021;22(2):1499 [Crossref]
15- Salod Z, Mahomed O. Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017–2021—A Scoping Review. Vaccines. 2022;10(11):1785 [Crossref]
16- Zou M, Lei C, Huang D, Liu L, Han Y. Application of plant-derived products as adjuvants for immune activation and vaccine development. Vaccine. 2024; [Crossref]
17- EL Khatabi K, Aanouz I, Alaqarbeh M, Ajana M, Lakhlifi T, Bouachrine M. Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MPro). Bioimpacts. 2021;12(2):107 [Crossref]
18- Khan T, Khan A, Ansari J, Najmi M, Wei D, Muhammad K, Waheed Y. Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach. Molecules. 2022;27(7):2375 [Crossref]
19- Maglioco A, Agüero F, Valacco M, Valdez A, Paulino M, Fuchs A. Characterization of the B-Cell Epitopes of Echinococcus granulosus Histones H4 and H2A Recognized by Sera From Patients With Liver Cysts. Front Cell Infect Microbiol. 2022;12 [Crossref]
20- Wei W, Wang L, Zhou P, Jiang B, Liu H, Feng L, Ge R, Tang F, Li R. Bioinformatic prediction and identification of immunogenic epitopes of the antigenic 14-3-3 protein of Echinococcus multilocularis. Acta Tropica. 2021;220:105955 [Crossref]
21- Basmenj E, Arastonejad M, Mamizadeh M, Alem M, KhalatbariLimaki M, Ghiabi S, Khamesipour A, Majidiani H, Shams M, Irannejad H. Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis. Sci Rep. 2023;13(1) [Crossref]
22- Thelen J, Leite W, Urban V, O’Neill H, Grishaev A, Curtis J, Krueger S, Castellanos M. Morphological Characterization of Self-Amplifying mRNA Lipid Nanoparticles. ACS Nano. 2024;18(2):1464 [Crossref]
23- Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in the field of cancer immunotherapy. Mol Cancer. 2023;22(1) [Crossref]
24- Mohammadzadeh R, Soleimanpour S, Pishdadian A, Farsiani H. Designing and development of epitope-based vaccines againstHelicobacter pylori. Critical Reviews in Microbiology. 2022;48(4):489 [Crossref]
25- Kordi B, Basmenj E, Majidiani H, Basati G, Sargazi D, Nazari N, Shams M, Shivahare R. In Silico Characterization of an Important Metacyclogenesis Marker in Leishmania donovani, HASPB1, as a Potential Vaccine Candidate. BioMed Research International. 2023;2023:1 [Crossref]
26- Wang D, Liu Y, Zhao W. The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine. Front Mol Biosci. 2021;8 [Crossref]
27- Pourseif M, Moghaddam G, Nematollahi A, Khordadmehr M, Naghili B, Dehghani J, Omidi Y. Vaccination with rEGVac elicits immunoprotection against different stages of Echinococcus granulosus life cycle: A pilot study. Acta Tropica. 2021;218:105883 [Crossref]
28- Masoudi-Sobhanzadeh Y, Esmaeili H, Masoudi-Nejad A. A fuzzy logic-based computational method for the repurposing of drugs against COVID-19. Bioimpacts. 2022;12(4):315 [Crossref]
29- Dehghani A, Mamizadeh M, Karimi A, Hosseini S, Siamian D, Shams M, Ghiabi S, Basati G, Abaszadeh A. Multi-epitope vaccine design against leishmaniasis using IFN-γ inducing epitopes from immunodominant gp46 and gp63 proteins. Journal of Genetic Engineering and Biotechnology. 2024;22(1):100355 [Crossref]
30- Deo S, Desai K, Patare A, Wadapurkar R, Rade S, Mahudkar S, Sathe M, Srivastava S, Prasanna P, Singh A. Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies. Biochemical and Biophysical Research Communications. 2023;680:108 [Crossref]
31- Han Y, Jia Z, Shi J, Wang W, He K. The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis. Bioimpacts. 2021;12(2):139 [Crossref]
32- Masoudi-Sobhanzadeh Y, Jafari B, Parvizpour S, Pourseif M, Omidi Y. A novel multi-objective metaheuristic algorithm for protein-peptide docking and benchmarking on the LEADS-PEP dataset. Computers in Biology and Medicine. 2021;138:104896 [Crossref]
33- Lotfi F, Akbarzadeh-Khiavi M, Lotfi Z, Rahbarnia L, Safary A, Zarredar H, Baghbanzadeh A, Naghili B, Baradaran B. Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. Infection. 2021;49(6):1133 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge